Clinical Trial Update: A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) [Phase 1, Phase 2]

View source ↗

Summary

GFH009 is being studied as a single-agent therapy in relapsed or refractory Peripheral T-cell Lymphoma, with Phase 1/2 trials currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• GFH009 (GFH009)

Snippet

Sponsor: Genfleet Therapeutics (Shanghai) Inc. | Conditions: Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | Phase 1, Phase 2 | Status: RECRUITING